Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT07713537
Recruiting Observational

Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy

NCT07713537 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Phase
Observational
Started
2025-01-01
Last updated
2026-07-20

Condition(s) studied

Atrial Fibrillation (AF)Ischemic Stroke

Investigational drug(s) / intervention(s)

DOAC Level

DOAC Level: Testing for plasma DOAC level concentration to determine 'on-therapy' status

Study summary

Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patient over 18 years of age * History of AD * Currently on DOACs. * Capacity to understand the study procedures and provide informed consent. Exclusion Criteria: * Patient with valvular AF (mitral stenosis) or mechanical valve prostheses. * Unable to complete a follow-up period of at least 3 months from enrollment.

Primary outcome measure(s)

  • Stroke Risk Scale — From January 2023 to December 2027
    To design and validate a stroke risk scale specific to AF patients undergoing DOAC therapy (target patients), through retrospective analysis of a population sample, based on demographic, clinical, socioeconomic and gender factors; as well as other newly identified factors.

Trial sites (2)

FacilityCityRegionStatus
Germans Trias University Hospital Barcelona Barcelona Recruiting
Vall d'Hebron University Hospital Barcelona Barcelona Recruiting

More Hospital Universitari Vall d'Hebron Research Institute trials in Spain

Integrative Diagnosis for SCD and Other RADs Recruiting
Immunological Reset to Allow Access to HLA Compatible Transplantation in Highly Sensitized Kidney Transplant Candidates Through Non-myeloablative Autologous Stemm Cell Transplantation Recruiting
Migraine and Endometriosis: The FEMININE Study Starting soon
Accelerating Referral for Thrombectomy in Acute Stroke Patients Using an Artificial Intelligence-based Software Recruiting
Smartwatch and External Holter Monitoring to Detect Atrial Fibrillation in Patients With Cryptogenic Stroke Recruiting

Other trials for the same condition

A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation Active, not recruiting
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration Recruiting
OPTION-EMEA Clinical Trial Recruiting
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial Active, not recruiting
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07713537 on ClinicalTrials.gov ↗ ← All trials in Spain